Interferon-omega: Current status in clinical applications

International Immunopharmacology

Volumn 52, Issue , 2017, Pages 253-260

  Li, Shi fang ^a,b   Zhao, Fu rong ^a,b   Shao, Jun jun ^a,b   Xie, Yin li ^a,b   Chang, Hui yun ^a,b   Zhang, Yong guang ^a,b  

^a INSTITUTE OF PLANT PROTECTION   (China)

^b YANGZHOU UNIVERSITY   (China)

Author keywords

Application; Biological activity; Interferon omega; Type I IFN

Indexed keywords

INTERFERON; INTERFERON OMEGA; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; INTERFERON OMEGA 1; RECOMBINANT PROTEIN;

ANIMAL DISEASE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; ATOPIC DERMATITIS; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; CANINE ATOPIC DERMATITIS; COWPOX VIRUS; ENDOGENOUS RETROVIRUS; FELINE CALICIVIRUS; FELINE CHRONIC GINGIVOSTOMATITIS SYNDROME; FELINE IMMUNODEFICIENCY VIRUS; FELINE INFECTIOUS PERITONITIS; FELINE LEUKEMIA VIRUS; FIBROSARCOMA; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; NONHUMAN; PARVOVIRIDAE; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION; ANIMAL; CAT; DOG; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOUSE; PROCEDURES;

ANIMALS; ANTIVIRAL AGENTS; CATS; DOGS; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE I; MICE; RECOMBINANT PROTEINS; VIRUS DISEASES;

EID: 85029794169     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2017.08.028     Document Type: Review

References (109)

1. Isaacs, A., Lindenmann, J., Virus interference. I, the interferon. J. Immunol. 195 (2015), 1911–1920.
2. Tian, L., Zhao, P., Ma, B., Guo, G., Sun, Y., Xing, M., Cloning, expression and antiviral bioactivity of red-crowned crane interferon-alpha. Gene 544 (2014), 49–55.
3. Cheng, G., Chen, W., Li, Z. et al., Characterization of the porcine alpha interferon multigene family. Gene 382 (2006), 28–38.
4. Pitha, P.M., Kunzi, M.S., Type I interferon: the ever unfolding story. Interferon: The 50th Anniversary, 316, 2007, 41–70.
5. Roberts, R.M., Liu, L.M., Alexenko, A., New and atypical families of type I interferons in mammals: comparative functions, structures, and evolutionary relationships. Prog. Nucleic Acid Res. Mol. Biol. 56 (1997), 287–325.
6. Kotenko, S.V., Gallagher, G., Baurin, V.V. et al., IFN-lambda s mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4 (2003), 69–77.
7. Sheppard, P., Kindsvogel, W., WF, Xu et al., IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4 (2003), 63–68.
8. Hauptmann, R., Swetly, P., A novel class of human type I interferons. Nucleic Acids Res. 13 (1985), 4739–4749.
9. Freaney, J.E., Zhang, Q., Yigit, E., Kim, R., Widom, J., Wang, J.P., Horvath, C.M., High-density nucleosome occupancy map of human chromosome 9p21-22 reveals chromatin organization of the type I interferon gene cluster. J. Interf. Cytokine Res. 34 (2014), 676–685.
10. Yang, L.M., Xue, Q.H., Sun, L., Zhu, Y.P., Liu, W.J., Cloning and characterization of a novel feline IFN-omega. J. Interf. Cytokine Res. 27 (2007), 119–127.
11. Goodbourn, S., Didcock, L., Randall, R.E., Interferons: cell signalling, immune modulation, antiviral responses and virus countermeasures. J. Gen. Virol. 81 (2000), 2341–2364.
12. Adolf, G.R., Frühbeis, B., Hauptmann, R. et al., Human interferon omega 1: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein. Biochim. Biophys. Acta. 1089 (1991), 167–174.
13. Seo, Y., Kim, M., Choi, M. et al., Possible role of phosphoinositide-3-kinase in Mx1 protein translation and antiviral activity of interferon-omega-stimulated HeLa cells. Pharmacology 87 (2011), 224–231.
14. Adolf, G.R., Human interferon omega—a review. Mult. Scler. Suppl. 1 (1995), S44–7.
15. Tiefenthaler, M., Geisen, F., Schirmer, M., Konwalinka, G., A comparison of the antiproliferative properties of recombinant human IFN-alpha 2 and IFN-omega in human bone marrow culture. J. Interf. Cytokine Res. 17 (1997), 327–329.
16. Nakamura, N., Sudo, T., Matsuda, S., Yanai, A., Molecular cloning of feline interferon cDNA by direct expression. Biosci. Biotechnol. Biochem. 56 (1992), 211–214.
17. Mege, D., Lefevre, F., Labonnardiere, C., The porcine family of interferon-omega: cloning, structural analysis, and functional studies of five related genes. J. Interf. Res. 11 (1991), 341–350.
18. Detournay, O., Morrison, D.A., Wagner, B., Zarnegar, B., Wattrang, E., Genomic analysis and mRNA expression of equine type I interferon genes. J. Interf. Cytokine Res. 33 (2013), 746–759.
19. Charlier, M., L'Haridon, R., Boisnard, M., Cloning and structural analysis of four genes encoding interferon-omega in rabbit. J. Interf. Res. 13 (1993), 313–322.
20. He, X., Korytar, T., Schatz, J., Freuling, C.M., Mueller, T., Koellner, B., Anti-lyssaviral activity of Interferons kappa and omega from the serotine bat, Eptesicus serotinus. J. Virol. 88 (2014), 5444–5454.
21. Cross, J.C., Roberts, R.M., Constitutive and trophoblast-specific expression of a class of bovine interferon genes. Proc. Natl. Acad. Sci. U. S. A. 88 (1991), 3817–3821.
22. Leaman, D.W., Roberts, R.M., Genes for the trophoblast interferons in sheep, goat, and musk ox and distribution of related genes among mammals. J. Interf. Res. 12 (1992), 1–11.
23. Bekisz, J., Schmeisser, H., Hernandez, J., Goldman, N.D., Zoon, K.C., Human interferons alpha, beta and omega. Growth Factors 22 (2004), 243–251.
24. Yang, L.M., Xue, Q.H., Sun, L., Zhu, Y.P., Liu, W.J., Cloning and characterization of a novel feline IFN-omega. J. Interf. Cytokine Res. 27 (2007), 119–127.
25. Sang, Y., Rowland, R.R., Hesse, R.A., Blecha, F., Differential expression and activity of the porcine type I interferon family. Physiol. Genomics 42 (2010), 248–258.
26. Zhao, X., Cheng, G., Yan, W., Liu, M., He, Y., Zheng, Z., Characterization and virus-induced expression profiles of the porcine interferon-omega multigene family. J. Interf. Cytokine Res. 29 (2009), 687–693.
27. Himmler, A., Hauptmann, R., Adolf, G.R., Swetly, P., Molecular cloning and expression in Escherichia coli of equine type I interferons. DNA 5 (1986), 345–356.
28. An, D., Guo, Y., Bao, J., Luo, X., Liu, Y., Ma, B., Gao, M., Wang, J., Molecular characterization and biological activity of bovine interferon-omega3. Res. Vet. Sci. 115 (2017), 125–131.
29. Luo, X., Guo, Y., Bao, J. et al., Characterization and antivirus activities of a novel bovine IFN-omega24. Mol. Immunol. 66 (2015), 357–363.
30. Adolf, G.R., Maurer-Fogy, I., Kalsner, I., Cantell, K., Purification and characterization of natural human interferon omega 1. Two alternative cleavage sites for the signal peptidase. J. Biol. Chem. 265 (1990), 9290–9295.
31. Rodríguez, M., Martínez, V., Alazo, K., Suárez, M., Redondo, M., Montero, C., Besada, V., de la Fuente, J., The bovine IFN-omega 1 is biologically active and secreted at high levels in the yeast Pichia pastoris. J. Biotechnol. 60 (1998), 3–14.
32. Liu, L., Leaman, D.W., Bixby, J.A., Roberts, R.M., A type I ovine interferon with limited similarity to IFN-alpha, IFN-omega and IFN-tau: gene structure, biological properties and unusual species specificity. Biochim. Biophys. Acta. 1294 (1996), 55–62.
33. Wetzel, R., Assignment of the disulphide bonds of leukocyte interferon. Nature 289 (1981), 606–607.
34. Skorvanova, L., Svancarova, P., Svetlikova, D., Betakova, T., Protective efficacy of IFN-omega AND IFN-lambda s against influenza viruses in induced A549 cells. Acta Virol. 59 (2015), 413–417.
35. Ce, Xu, Song, X., Fu, L. et al., Antiviral potential of exogenous human omega interferon to inhibit pandemic 2009A (H1N1) influenza virus. Viral Immunol. 24 (2011), 369–374.
36. Buckwold, V.E., Lang, W., Scribner, C., Blanchett, D., Alessi, T., Langecker, P., Safety pharmacology, toxicology and pharmacokinetic assessment of recombinant human omega-interferon produced from CHO-SS cells. Basic Clin. Pharmacol. Toxicol. 99 (2006), 62–70.
37. Xue, X., Li, D., Yu, J., Ma, G., Su, Z., Hu, T., Phenyl linker-induced dense PEG conformation improves the efficacy of C-terminally mono PEGylated staphylokinase. Biomacromolecules 14 (2013), 331–341.
38. Yu, W., Yu, C., Wu, L. et al., PEGylated recombinant human interferon-omega as a long-acting antiviral agent: structure, antiviral activity and pharmacokinetics. Antivir. Res. 108 (2014), 142–147.
39. Huang, C., Receptor-Fc fusion therapeutics, traps, and MIMETIBODY (TM) technology. Curr. Opin. Biotechnol. 20 (2009), 692–699.
40. Li, J., Li, B., Zhang, J. et al., Preparation of CHO cell-derived rhIFN-omega-Fc with improved pharmacokinetics. Antivir. Res. 89 (2011), 199–203.
41. Buckwold, V.E., Wei, J., Huang, Z. et al., Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses. Antivir. Res. 73 (2007), 118–125.
42. Buckwold, V.E., Wei, J.Y., Wenzel-Mathers, M., Russell, J., Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication. Antimicrob. Agents Chemother. 47 (2003), 2293–2298.
43. Gorbakov, V.V., Kim, H., Oronsky, B., Lang, W., HCV RNA results from a phase II, randomized, open-label study of omega interferon (IFN) with or without ribavirin in IFN-naive genotype 1 chronic HCV patients. Hepatology, 42, 2005, 705A.
44. Leal, R.O., Gil, S., Sepulveda, N. et al., Monitoring acute phase proteins in retrovirus infected cats undergoing feline interferon-omega therapy. J. Small Anim. Pract. 55 (2014), 39–45.
45. Domenech, A., Miro, G., Collado, V.M. et al., Use of recombinant interferon omega in feline retrovirosis: from theory to practice. Vet. Immunol. Immunopathol. 143 (2011), 301–306.
46. de Mari, K., Maynard, L., Sanquer, A., Lebreux, B., Eun, H.M., Therapeutic effects of recombinant feline interferon-omega on feline leukemia virus (FeLV)-infected and FeLV/feline immunodeficiency virus (FIV)-coinfected symptomatic cats. J. Vet. Intern. Med. 18 (2004), 477–482.
47. Gil, S., Leal, R.O., Duarte, A. et al., Relevance of feline interferon omega for clinical improvement and reduction of concurrent viral excretion in retrovirus infected cats from a rescue shelter. Res. Vet. Sci. 94 (2013), 753–763.
48. Kuwabara, M., Naria, Y., Horiuchi, Y. et al., Immunological effects of recombinant feline interferon-omega (KT-80) administration in the dog. Microbiol. Immunol. 50 (2006), 637–641.
49. Leal, R.O., Gil, S., Duarte, A. et al., Evaluation of viremia, proviral load and cytokine profile in naturally feline immunodeficiency virus infected cats treated with two different protocols of recombinant feline interferon omega. Res. Vet. Sci. 99 (2015), 87–95.
50. Sandoval, R., Xue, J.P., Pilkinton, M., Salvi, D., Kiyokawa, H., Colamonici, O.R., Different requirements for the cytostatic and apoptotic effects of type I interferons-induction of apoptosis requires ARF but not p53 in osteosarcoma cell lines. J. Biol. Chem. 279 (2004), 32275–32280.
51. Penzo, C., Ross, M., Muirhead, R., Else, R., Argyle, D.J., Effect of recombinant feline interferon- alone and in combination with chemotherapeutic agents on putative tumour-initiating cells and daughter cells derived from canine and feline mammary tumours. Vet. Comp. Oncol. 7 (2009), 222–229.
52. Villaverde, M.S., Gil-Cardeza, M.L., Glikin, G.C., Finocchiaro, L.M.E., Interferon-beta lipofection II. Mechanisms involved in cell death and bystander effect induced by cationic lipid-mediated interferon-beta gene transfer to human tumor cells. Cancer Gene Ther. 19 (2012), 420–430.
53. Chen, P.F., GF, Fu, Zhang, H.Y., GX, Xu, Hou, Y.Y., Liposomal plasmid DNA encoding human thymosin alpha(1) and interferon omega(1) potently inhibits liver tumor growth in ICR mice. J. Gastroenterol. Hepatol. 21 (2006), 1538–1543.
54. Horton, H.M., Hernandez, P., Parker, S.E. et al., Antitumor effects of interferonomega: in vivo therapy of human tumor xenografts in nude mice. Cancer Res., 59, 1999.
55. Husebye, E.S., Perheentupa, J., Rautemaa, R., Kampe, O., Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J. Intern. Med. 265 (2009), 514–529.
56. Ueda, Y., Sakurai, T., Kasama, K., Satoh, Y., Atsumi, K., Hanawa, S. et al., Pharmacokinetic properties of recombinant feline interferon and its stimulatory effect on 2′,5′-oligoadenylate synthetase activity in the cat. J. Vet. Med. Sci. 55 (1993), 1–6.
57. Knebi, A., Schulz, B., Helps, C., Sauter-Louis, C., Mueller, R.S., Hartmann, K., Topical application of recombinant feline interferon-omega in cats with feline calicivirus or feline herpesvirus-1 infection. Kleintierpraxis, 59, 2014, 642.
58. Hennet, P.R., Camy, G.A.L., McGahie, D.M., Albouy, M.V., Comparative efficacy of a recombinant feline interferon omega in refractory cases of calicivirus-positive cats with caudal stomatitis: a randomised, multi-centre, controlled, double-blind study in 39 cats. J. Feline Med. Surg. 13 (2011), 577–587.
59. Addie, D., Belak, S., Boucraut-Baralon, C. et al., Feline infectious peritonitis. ABCD guidelines on prevention and management. J. Feline Med. Surg. 11 (2009), 594–604.
60. Mihaljevic, S.Y., First clinical Experiences With Omega-interferon in the Treatment of Chronic Gingivitis-Stomatitis-Oropharyngitis of Cats. vol. 84, 2003, Praktische Tierarzt, 350–361.
61. Slack, J.M., Stiles, J., Leutenegger, C.M., Moore, G.E., Pogranichniy, R.M., Effects of topical ocular administration of high doses of human recombinant interferon alpha-2b and feline recombinant interferon omega on naturally occurring viral keratoconjunctivitis in cats. Am. J. Vet. Res. 74 (2013), 281–289.
62. Khan, H., Hill, A., Main, J., Brown, A., Cooke, G., Can hepatitis C virus antigen testing replace ribonucleic acid polymearse chain reaction analysis for detecting hepatitis C virus? A systematic review. Open Forum Infect. Dis., 4, 2017, ofw252.
63. Alter, H.J., Seeff, L.B., Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin. Liver Dis. 20 (2000), 17–35.
64. Kim, H., Jeon, S., Natural history of hepatitis C virus (HCV) infection in Korean hemophiliacs. Haemophilia, 20, 2014, 38.
65. El-Raziky, M.S., Halawa, E.F., Draz, I.H., Ali, M.S., Natural history and response to treatment of HCV infection among Egyptian survivors of childhood malignancy. Pediatr. Hematol. Oncol. 32 (2015), 138–145.
66. Gronbaek, K., Krarup, H.B., Ring-Larsen, H. et al., Interferon alfa-2b alone or combined with recombinant granulocyte-macrophage colony-stimulating factor as treatment of chronic hepatitis C. Scand. J. Gastroenterol. 37 (2002), 840–844.
67. Okuse, C., Rinaudo, J.A., Farrar, K., Wells, F., Korba, B.E., Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy. Antivir. Res. 65 (2005), 23–34.
68. Zhu, W., Hu, Z., Liao, X., Chen, X., Huang, W., Zhong, Y., Zeng, Z., A new mutation site in the AIRE gene causes autoimmune polyendocrine syndrome type 1. Immunogenetics, 2017.
69. Li, D., Streeten, E.A., Chan, A., Lwin, W., Tian, L., Pellegrino da Silva, R., Kim, C.E., Anderson, M.S., Hakonarson, H., Levine, M.A., Exome sequencing reveals mutations in AIRE as a cause of isolated hypoparathyroidism. J. Clin. Endocrinol. Metab. 102 (2017), 1726–1733.
70. Meager, A., Visvalingam, K., Peterson, P. et al., Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 3 (2006), 1152–1164.
71. Breivik, L., Oftedal, B.E.V., Wolff, A.S.B., Bratland, E., Orlova, E.M., Husebye, E.S., A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with autoimmune polyendocrine syndrome type 1. Clin. Immunol. 153 (2014), 220–227.
72. Wolff, A.S., Erichsen, M.M., Meager, A., Magitta, N.F., Myhre, A.G., Bollerslev, J., Fougner, K.J., Lima, K., Knappskog, P.M., Husebye, E.S., Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. J. Clin. Endocrinol. Metab. 92 (2007), 595–603.
73. Zhang, L., Barker, J.M., Babu, S. et al., A robust immunoassay for anti-interferon autoantibodies that is highly specific for patients with autoimmune polyglandular syndrome type 1. Clin. Immunol. 125 (2007), 131–137.
74. Oftedal, B.E., Wolff, A.S.B., Bratland, E. et al., Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clin. Immunol. 129 (2008), 163–169.
75. Larosa, M.D., Mackenzie, R., Burne, P., Garelli, S., Barollo, S., Masiero, S., Rubin, B., Chen, S., Furmaniak, J., Betterle, C., Smith, B.R., Assessment of autoantibodies to interferon-ω in patients with autoimmune polyendocrinesyndrome type 1: using a new immunoprecipitation assay. Clin. Chem. Lab. Med., 2017.
76. Coyne, K.P., Jones, B.R., Kipa, A. et al., Lethal outbreak of disease associated with feline calicivirus infection in cats. Vet. Rec 158 (2006), 544–550.
77. Olspert, A., Hosmillo, M., Chaudhry, Y., Peil, L., Truve, E., Goodfellow, I., Protein-RNA linkage and posttranslational modifications of feline calicivirus and murine norovirus VPg proteins. PeerJ, 4, 2016, e2134.
78. Ohe, K., Takahashi, T., Hara, D., Hara, M., Sensitivity of FCV to recombinant feline interferon (rFeIFN). Vet. Res. Commun. 32 (2008), 167–174.
79. McDonagh, P., Sheehy, P.A., Fawcett, A., Norris, J.M., Antiviral effect of mefloquine on feline calicivirus in vitro. Vet. Microbiol. 176 (2015), 370–377.
80. Lee, M.H., Seo, D.J., Kang, J.H., SH, Oh., Choi, C., Expression of antiviral cytokines in Crandell-Reese feline kidney cells pretreated with Korean red ginseng extract or ginsenosides. Food Chem. Toxicol. 70 (2014), 19–25.
81. Aboubakr, H.A., Nauertz, A., Luong, N.T., Agrawal, S., El-Sohaimy, S.A., Youssef, M.M., Goyal, S.M., In vitro antiviral activity of clove and ginger aqueous extracts against feline calicivirus, a surrogate for human norovirus. J. Food Prot. 79 (2016), 1001–1012.
82. Uchino, T., Ishii, S., Inoue, K., Inoue, M., Uno, T., Okusa, K., Obayasi, K., Okuda, A., Kanemoto, I., Kanakura, H. et al., A large-scale field study of feline interferon on feline calicivirus infection. Japanese. J. Small Anim. Pract. 18 (1999), 7–17.
83. Verneuil, M., Topical application of feline interferon omega in the treatment of herpetic keratitis in the cat: preliminary study. Proceedings of the International Veterinary Ophthalmology Meeting. Munich, Germany, 2004, 427.
84. Haid, C., Kaps, S., Gönczi, E., Hässig, M., Metzler, A., Spiess, B.M., Richter, M., Pretreatment with feline interferon omega and the course of subsequent infection with feline herpesvirus in cats. Vet. Ophthalmol. 10 (2007), 278–284.
85. Ballin, A.C., Schulz, B., Helps, C., Sauter-Louis, C., Mueller, R.S., Hartmann, K., Limited efficacy of topical recombinant feline interferon-omega for treatment of cats with acute upper respiratory viral disease. Vet. J. 202 (2014), 466–470.
86. Westman, M.E., Malik, R., Hall, E., Sheehy, P.A., Norris, J.M., Comparison of three feline leukaemia virus (FeLV) point-of-care antigen test kits using blood and saliva. Comp. Immunol. Microbiol. Infect. Dis. 50 (2017), 88–96.
87. Terry, A., Kilbey, A., Naseer, A., Levy, L.S., Ahmad, S., Watts, C., Mackay, N., Cameron, E., Wilson, S., Neil, J.C., Barriers to infection of human cells by feline leukemia virus: insights into resistance to zoonosis. J. Virol. 91 (2017), e02119–16.
88. Collado, V.M., Gomez-Lucia, E., Tejerizo, G. et al., Effect of type I interferons on the expression of feline leukaernia virus. Vet. Microbiol. 123 (2007), 180–186.
89. Pedersen, N.C., Ho, E.W., Brown, M.L., Yamamoto, J.K., Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science (USA) 235 (1987), 790–793.
90. Bendinelli, M., Pistello, M., Lombardi, S. et al., Feline immunodeficiency virus-an interesting model for aids studies and an important cat pathogen. Clin. Microbiol. Rev. 8 (1995), 87–112.
91. Arjona, A., Escolar, E., Soto, I., Barquero, N., Martin, D., Gomez-Lucia, E., Seroepidemiological survey of infection by feline leukemia virus and immunodeficiency virus in Madrid and correlation with some clinical aspects. J. Clin. Microbiol. 38 (2000), 3448–3449.
92. Gil, S., Leal, R.O., McGahie, D. et al., Oral recombinant feline interferon-omega as an alternative immune modulation therapy in FIV positive cats: clinical and laboratory evaluation. Res. Vet. Sci. 96 (2014), 79–85.
93. Willett, B.J., Hosie, M.J., Feline leukaemia virus: half a century since its discovery. Vet. J. 195 (2013), 16–23.
94. Westman, M.E., Malik, R., Hall, E., Norris, J.M., Diagnosing feline immunodeficiency virus (FIV) infection in FIV-vaccinated and FIV-unvaccinated cats using saliva. Comp. Immunol. Microbiol. Infect. Dis. 46 (2016), 66–72.
95. Leal, R.O., Gil, S., Brito, M.T.V., McGahie, D., Niza, M.M.R.E., Tavares, L., The use of oral recombinant feline interferon omega in two cats with type II diabetes mellitus and concurrent feline chronic gingivostomatitis syndrome. Ir. Vet. J., 66, 2013, 19.
96. Parrish, C.R., Carmichael, L.E., Antigenic structure and variation of canine parvovirus type-2, feline panleukopenia virus, and mink enteritis virus. Virology 129 (1983), 401–414.
97. Martin, V., Najbar, W., Gueguen, S. et al., Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled challenge trial. Vet. Microbiol. 89 (2002), 115–127.
98. Minagawa, T., Ishiwata, K., Kajimoto, T., Feline interferon-omega treatment on canine parvovirus infection. Vet. Microbiol. 69 (1999), 51–53.
99. Appl, C., von Bomhard, W., Hanczaruk, M., Meyer, H., Bettenay, S., Mueller, R., Feline cowpoxvirus infections in Germany: clinical and epidemiological aspects. Berl. Munch. Tierarztl. Wochenschr. 126 (2013), 55–61.
100. Altmann, S.E., Brandt, C.R., Jahrling, P.B., Blaney, J.E., Antiviral activity of the EB peptide against zoonotic poxviruses. Virol. J., 9, 2012, 6.
101. McInerney, J., Papasouliotis, K., Simpson, K. et al., Pulmonary cowpox in cats: five cases. J. Feline Med. Surg. 18 (2016), 518–525.
102. Enos, T., Hosler, G.A., Uddin, N., Mir, A., Congenital infantile fibrosarcoma mimicking a cutaneous vascular lesion: a case report and review of the literature. J. Cutan. Pathol. 44:2017 (2017), 193–200.
103. Hampel, V., Schwarz, B., Kempf, C. et al., Adjuvant immunotherapy of feline fibrosarcoma with recombinant feline interferon-omega. J. Vet. Intern. Med. 21 (2007), 1340–1346.
104. Olivry T, DJ, DeBoer, Favrot, C., Jackson, H.A., Mueller, R.S., Nuttall, T., Prélaud, P., International Task Force on Canine Atopic Dermatitis, Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet. Dermatol. 21 (2010), 233–248.
105. Carlotti, D.N., Boulet, M., Ducret, J. et al., The use of recombinant omega interferon therapy in canine atopic dermatitis: a double-blind controlled study. Kleintierpraxis, 57, 2012 (135-+).
106. Litzlbauer, P., Weber, K., Mueller, R.S., Oral and subcutaneous therapy of canine atopic dermatitis with recombinant feline interferon omega. Cytokine 66 (2014), 54–59.
107. Tekes, G., Thiel, H.J., Feline coronaviruses, pathogenesis of feline infectious peritonitis. Adv. Virus Res. 96 (2016), 193–218.
108. Hartmann, K., Binder, C., Hirschberger, J. et al., Comparison of different tests to diagnose feline infectious peritonitis. J. Vet. Intern. Med. 17 (2003), 781–790.
109. Ritz, S., Egberink, H., Hartmann, K., Effect of feline interferon-omega on the survival time and quality of life of cats with feline infectious peritonitis. J. Vet. Intern. Med. 21 (2007), 1193–1197.